Session » Rheumatoid Arthritis - Clinical Aspects II: Identifying Rheumatoid Arthritis in At-Risk Populations

Meeting: 2013 ACR/ARHP Annual Meeting

Abstract Number: 868

Serum Immunoglobulin Free Light Chains and Rheumatoid Arthritis: A Population-Based Study

Abstract Number: 869

Anti-Carbamylated Protein Antibodies Are Present Prior To The Diagnosis Of Rheumatoid Arthritis and Predict Future Disease Onset

Abstract Number: 870

How To Predict That Early Arthritis Without Rheumatoid Factor and ACPA Becomes Rheumatoid Arthritis According To ACR/EULAR 2010 After a 3-Years Follow-Up? Results From The Espoir Cohort

Abstract Number: 871

Do We Need To Lower The Cut Point Of The 2010 ACR/EULAR Classification Criteria For Diagnosing Rheumatoid Arthritis?!

Abstract Number: 872

Spontaneous Remission In Patients Fulfilling The 2010 Classification Criteria For Rheumatoid Arthritis: The Impact Of Duration Of Joint Swelling

Abstract Number: 873

Health Fair Evaluations To Identify Subjects At-Risk For Future Inflammatory Arthritis and Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.